Skip to main content
    X

    Xenetic Biosciences Inc (XBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.48
    -0.18 (-10.84%)

    Market Cap: $3.89M

    Last updated: Nov 17, 2026 at 8:24 AM ET

    Xenetic Biosciences Inc (XBIO) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Xenetic Biosciences (XBIO) to earn -$3.32 per share in the fiscal year ending Dec 31, 2026. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.34.

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss.

    Fiscal year ending Dec 31, 2026
    -$3.32
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$0.34
    EPS consensus, revenue $1.90M
    Next report
    Mar 10, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$3.32-$3.32 to -$3.321N/AN/A0
    Dec 31, 2027-$0.34-$0.34 to -$0.341$1.90M$1.90M to $1.90M1

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$4.46.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$3.32-$3.32-$3.32-$3.32-$4.46N/A
    Fiscal year ending Dec 31, 2027-$0.34-$0.34-$0.34-$0.34-$0.43N/A

    Frequently Asked Questions About XBIO

    What is the XBIO stock forecast?

    Consensus analyst estimates put Xenetic Biosciences's EPS at -$3.32 for the fiscal year ending Dec 31, 2026.

    What EPS do analysts expect from XBIO next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.32, with estimates from -$3.32 to -$3.32 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.34, with estimates from -$0.34 to -$0.34 from 1 analyst.

    What revenue do analysts expect from Xenetic Biosciences next year?

    For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.90M, with estimates from $1.90M to $1.90M.

    How many analysts cover XBIO?

    1 analyst estimates EPS for Xenetic Biosciences for the fiscal year ending Dec 31, 2026.